%0 Journal Article
%T Treatment Patterns and Mortality Risk among Elderly Patients with Metastatic Triple Negative Breast Cancer in the United States: An Observational Cohort Study Using SEER-Medicare Data
%A Sacha Satram-Hoang
%A Preeti Bajaj
%A Alisha Stein
%A Patricia Cortazar
%A Faiyaz Momin
%A Carolina Reyes
%J Journal of Cancer Therapy
%P 117-133
%@ 2151-1942
%D 2019
%I Scientific Research Publishing
%R 10.4236/jct.2019.102009
%X <em>Purpose</em><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">:
Triple negative breast cancer is more aggressive than other breast cancer
subtypes and accounts for up to 20% of all breast cancer</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">s</span></span></span><span><span><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\">.
Despite the poorer prognosis, there are no approved targeted treatments
available and chemotherapy remains the only choice. We examined treatment
patterns and outcomes among elderly metastatic triple-negative breast cancer
(mTNBC) patients in routine clinical practice. </span><i><span style=\"font-family:Verdana;\">Methods</span></i><span style=\"font-family:Verdana;\">:</span><i> </i><span style=\"font-family:Verdana;\">Patients were
identified from the linked SEER-Medicare database between 1/1/2001</span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"> and </span></span></span><span><span><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\">12/31/2013 and included </span><i><span style=\"font-family:Verdana;\">de novo</span></i><span style=\"font-family:Verdana;\"> Stage IV (n = 776) and patients with distant metastasis follow</span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">ed</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"> an
initial diagnosis of Stage I</span></span></span><span><span><span style=\"font-family:;\" \"=\"\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">-</span></span></span><span><span><span style=\"font-family:;\" \"=\"\"> </span></span></span><span><span><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\">III
disease (n = 1851). Kaplan-Meier analyses and time-varying Cox proportional
hazards regression were used to assess overall survival (OS). </span><i><span style=\"font-family:Verdana;\">Results</span></i><span style=\"font-family:Verdana;\">:</span><b> </b><span style=\"font-family:Verdana;\">The mean age at
metastatic diagnosis was 77.6 years and 1259 (48%) patients received
chemotherapy. Compared to &lt;70 year olds, ¡Ý70 year olds had worse
%K Triple Negative Breast Cancer
%K Elderly Patients
%K Chemotherapy
%K Survival
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=90519